Show simple item record

dc.contributor.author Tihon, Beatricie-Marinela
dc.date.accessioned 2024-10-28T12:50:28Z
dc.date.accessioned 2024-11-18T21:30:36Z
dc.date.available 2024-10-28T12:50:28Z
dc.date.available 2024-11-18T21:30:36Z
dc.date.issued 2024
dc.identifier.citation TIHON, Beatricie-Marinela. The role of estrogens in cardiovascular disease. In: MedEspera: the 10th Intern. Medical Congress for Stud. and Young Doctors, 24-27 April 2024: abstract book. Chișinău, 2024, p. 334. ISBN 978-9975-3544-2-4. en_US
dc.identifier.isbn 978-9975-3544-2-4
dc.identifier.uri https://medespera.md/en/books?page=10
dc.identifier.uri https://repository.usmf.md/handle/20.500.12710/28742
dc.description Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica Moldova en_US
dc.description.abstract Introduction. Epidemiological studies have shown that 17beta-estradiol (E2) levels are inversely associated with cardiovascular disease (CVD) events in post-menopausal women. This indicates that estrogens have a possible implication in CVD pathogenesis, through their genomic and nongenomic mechanisms of action. Aim of study. Highlighting the role of estrogens and estrogen receptors in cardiovascular disease pathophysiology. Methods and materials. Publications from the last 5 years, from specialized journals of the PubMed databases, were selected and analyzed using the following keywords: estrogen, estrogen receptors, genomic and non-genomic mechanisms, cardiovascular disease. Results. Estrogens, through their specific receptors (ERα, ERβ and GPR30s), displayed prominent effects on cardiovascular disease pathogenesis. Evidence suggests their role in the management of systemic and pulmonary arterial hypertension, protecting against atherogenesis, ischemia-reperfusion injury, and safeguarding against heart failure with either reduced or preserved ejection fraction (EF). The specific mechanisms of ERα include reducing sympathetic outflow and endothelial dysfunction, decreasing fibrosis and pulmonary vascular remodeling, preserving EF, and enhancing systolic function. ERβ performs by decreasing vasoconstriction, vascular resistance and hypertrophy, mitigating fibrosis and inflammation, reducing apoptosis and preserving mitochondrial integrity, promoting cardiac angiogenesis and normalizing hemodynamic parameters. GPR30s mechanisms of action encompass relaxation of vascular smooth muscle, influence on nitric oxide synthesis, calcium level regulation, modulating cholesterol levels, and minimizing both inflammation and reactive oxygen species production. Conclusion. Estrogens displayed a possible involvement in managing cardiovascular disease, by reducing both the progression and severity of numerous cardiovascular pathologies through various genomic and non-genomic mechanisms of action. Elucidation of cardio protective mechanisms, determined by estrogens and estrogen receptors, will contribute to the development of effective therapeutic strategies for CVD treatment. en_US
dc.publisher Instituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldova en_US
dc.relation.ispartof MedEspera: The 10th International Medical Congress for Students and Young Doctors, 24-27 April 2024, Chișinău, Republic of Moldova en_US
dc.subject estrogen
dc.subject estrogen receptors
dc.subject genomic and non-genomic mechanisms
dc.subject cardiovascular disease
dc.title The role of estrogens in cardiovascular disease en_US
dc.type Other en_US


Files in this item

This item appears in the following Collection(s)

  • MedEspera 2024
    The 10th International Medical Congress for Students and Young Doctors, 24-27 April, 2024

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics